Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Slides:

Advertisements

Similar presentations

The prognostic importance of the number of involved lymph nodes in esophageal cancer: Implications for revisions of the American Joint Committee on Cancer.

Advertisements

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma Arianna.

Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data Chris R. Kelsey, MD, Kristin.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than.

Usman Ahmad, MD, Haoxian Yang, MD, Camelia Sima, MD, MS, Daniel H

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis Whitney S. Brandt, MD, Wanpu.

Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience Maria Teresa Congedo, MD, Alfredo Cesario,

Second Primary Lung Cancers: Smokers Versus Nonsmokers After Resection of Stage I Lung Adenocarcinoma R. Taylor Ripley, MD, Robert R. McMillan, MD, MPH,

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Randomized controlled trial of a special acupuncture technique for pain after thoracotomy Gary Deng, MD, PhD, Valerie Rusch, MD, Andrew Vickers, PhD,

Nael Martini, MDa, Manjit S. Bains, MDa, Michael E

The prognostic importance of the number of involved lymph nodes in esophageal cancer: Implications for revisions of the American Joint Committee on Cancer.

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non–small cell lung cancer

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer Stephen A. Barnett, MBBS, Robert.

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Thymic carcinoma outcomes and prognosis: Results of an international analysis Usman Ahmad, MD, Xiaopan Yao, PhD, Frank Detterbeck, MD, James Huang, MD,

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma Paul C. Lee, MD, Farooq M. Mirza, MD, Jeffrey.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Feiran Lou, MD, MS, Camelia S. Sima, MD, MS, Prasad S

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective Gaetano Rocco, MD, Katie Nason, MD, MPH, Alex Brunelli, MD, Gonzalo.

A first start for lung transplantation?

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients Raja.

Predictors of Nodal Metastases for Clinical T2N0 Esophageal Adenocarcinoma Arianna Barbetta, MD, Francisco Schlottmann, MD, Tamar Nobel, MD, David B.

A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage Sara de Cabanyes Candela, MD, Frank.

Yusuke Takahashi, MD, PhD, Prasad S. Adusumilli, MD

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the.

Attachment disorder in thoracoabdominal surgery

Bernard J. Park, MD, Raja M. Flores, MD, Valerie W. Rusch, MD

Process is helpful, but the procurement problem persists

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, Timothy Akhurst, MD, Mithat Gonen, PhD, Maureen Zakowski,

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Ventricular assistant in restrictive cardiomyopathy: Making the right connection Robert D.B. Jaquiss, MD The Journal of Thoracic and Cardiovascular Surgery

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Raja M. Flores, MD, Bernard J

Aritoshi Hattori, MD, Kenji Suzuki, MD

Who should decide margin length in pulmonary excision of lung cancer?

The clinical stage of non–small cell lung cancer as assessed by means of fluorodeoxyglucose–positron emission tomographic/computed tomographic scanning.

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Nael Martini, MDa, Valerie W. Rusch, MDa, Manjit S. Bains, MDa, Mark G

Michael J. Weyant, MD, Manjit S

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell lung cancer R. Taylor Ripley, MD, Kei Suzuki, MD, Kay See Tan, PhD, Prasad S. Adusumilli, MD, James Huang, MD, Bernard J. Park, MD, Robert J. Downey, MD, Nabil P. Rizk, MD, MS, Valerie W. Rusch, MD, Manjit Bains, MD, David R. Jones, MD The Journal of Thoracic and Cardiovascular Surgery Volume 151, Issue 4, Pages 969-979.e3 (April 2016) DOI: 10.1016/j.jtcvs.2015.09.127 Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Overall survival (OS). A, Entire cohort: the 5-year OS was 39% (95% confidence interval [CI], 28%-56%). B, Postinduction positron emission tomography (PET) N2 status: The 5-year OS for N2-negative was 43% (95% CI, 22%-83%) versus 39% (95% CI, 23%-64%) for N2-avid disease (P = .251). C, Pathologic N2 status: The 5-year OS for N2-negative was 40% (95% CI, 25%-64%) versus 38% (95% CI, 21%-67%) for N2-persistent disease (P = .936). D, Pathologic staging: The 5-year OS for < ypIIIA was 41% (95% CI, 25%-66%) versus 37% (95% CI, 21%-66%) for ≥ ypIIIA (P = .791). The Journal of Thoracic and Cardiovascular Surgery 2016 151, 969-979.e3DOI: (10.1016/j.jtcvs.2015.09.127) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Disease-free survival (DFS). A, Entire cohort: The 5-year DFS was 23% (95% confidence interval [CI], 14%-37%). B, Postinduction positron emission tomography (PET) N2 status: The 5-year DFS for N2-negative was 24% (95% CI, 11%-51%) versus 24% (95% CI, 11%-54%) for N2-avid disease (P = .867). C, Pathologic N2 status: The 5-year DFS for N2-negative was 34% (95% CI, 21%-56%) versus 9% (95% CI, 2%-45%) for N2-persistent disease (P = .079). D, Pathologic staging: The 5-year DFS for < ypIIIA was 36% (95% CI, 22%-58%) versus 9% (95% CI, 2%-44%) for ≥ ypIIIA (P = .054). The Journal of Thoracic and Cardiovascular Surgery 2016 151, 969-979.e3DOI: (10.1016/j.jtcvs.2015.09.127) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure E1 Cumulative incidence of recurrence (CIR). A, Entire cohort: The 5-year CIR was 70% (95% confidence interval [CI], 60%-81%). B, Postinduction positron emission tomography (PET) N2 status: The 5-year CIR for N2-negative was 76% (95% CI, 58%-99%) versus 58% (95% CI, 41%-80%) for N2-avid disease (Gray's test, P = .571). C, Pathologic N2 status: The 5-year CIR for N2-negative was 59% (95% CI, 44%-79%) versus 80% (95% CI, 66%-96%) for N2-persistent disease (Gray's test, P = .077). D, Pathologic staging: The 5-year CIR for < ypIIIA was 57% (95% CI, 41%-78%) versus 80% (95% CI, 67%-96%) for ≥ ypIIIA (Gray's test, P = .049). The Journal of Thoracic and Cardiovascular Surgery 2016 151, 969-979.e3DOI: (10.1016/j.jtcvs.2015.09.127) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Five-year overall survival was 43% for postinduction positron emission tomography N2-negative disease versus 39% for N2-avid disease. The Journal of Thoracic and Cardiovascular Surgery 2016 151, 969-979.e3DOI: (10.1016/j.jtcvs.2015.09.127) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions